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Identification of circulating microRNAs as diagnostic biomarkers
for use in multiple myeloma
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BACKGROUND: Multiple myeloma is a plasma cell disorder that is characterised by clonal proliferation of malignant plasma cells in the
bone marrow, monoclonal paraprotein in the blood or urine and associated organ dysfunction. It accounts for approximately 1% of
cancers and 13% of haematological cancers. Myeloma arises from an asymptomatic proliferation of monoclonal plasma cells termed
monoclonal gammopathy of undetermined significance (MGUS).
METHODS: MicroRNA expression profiling of serum samples was performed on three patient groups as well as normal controls.
Validation of the nine microRNAs detected as promising biomarkers was carried out using TaqMan quantitative reverse transcription
PCR. MicroRNA levels in serum were normalised using standard curves to determine the numbers of microRNAs per ml of serum.
RESULTS: Three serum microRNAs, miR-720, miR-1308 and miR-1246, were found to have potential as diagnostic biomarkers in
myeloma. Use of miR-720 and miR-1308 together provides a powerful diagnostic tool for distinguishing normal healthy controls, as
well as patients with unrelated illnesses, from pre-cancerous myeloma and myeloma patients. In addition, the combination of
miR-1246 and miR-1308 can distinguish MGUS from myeloma patients.
CONCLUSION: We have developed a biomarker signature using microRNAs extracted from serum, which has potential as a diagnostic
and prognostic tool for multiple myeloma.
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Multiple myeloma is a malignant disorder of bone marrow plasma
cells that accounts for approximately 13% of all haematological
cancers and 1% of all cancers (Terpos and Rahemtulla, 2005; Kyle
and Rajkumar, 2008). In multiple myeloma, malignant plasma
cells, which normally proliferate at a low rate, undergo a massive
clonal expansion resulting in high levels of production of
monoclonal immunoglobulin (Ig) (M-protein) or an Ig chain
(M-component) (Terpos and Rahemtulla, 2005) in the blood.
Because malignant plasma cells progressively infiltrate the bone
marrow, their proliferation interferes with cell signalling pathways
involved in osteoblast formation. The uncoupling of bone
resorption and formation leads to a rapid bone loss, osteoporosis,
lytic lesions and fractures. Hypercalcaemia as a result of loss of
calcium from the bone can cause life-threatening dehydration and
renal failure. Myeloma patients usually also have reduced levels of
normal Igs, resulting in severe immunodeficiency and suscept-
ibility to bacterial infections. Although myeloma is presently
incurable, recent advances in treatment, including the use of
thalidomide and newer agents such as the immunomodulatory
drug lenalidomide and the proteosome inhibitor bortezomib, as
well as autologous stem cell transplantation, can improve life
expectancy (Terpos and Rahemtulla, 2005; Kyle and Rajkumar,
2008).
Myeloma usually progresses from an asymptomatic pre-
cancerous stage of clonal plasma cell proliferation termed
‘monoclonal gammopathy of undetermined significance’ (MGUS).
The MGUS is present in more than 3% of the population above the
age of 50 and progresses to myeloma or a related malignancy at a
rate ofB1% per year (McKenna et al, 2008). A variant of MGUS is
asymptomatic or smouldering plasma cell myeloma where the
diagnostic criteria for multiple myeloma are met but there is no
related organ or tissue impairment (Kyle et al, 2007). Multiple
myeloma is characterised by various cytogenetic abnormalities,
some of which can be of prognostic significance. However, the
relevance of these chromosomal abnormalities to disease progres-
sion is unclear and none provide reliable predictors of survival
(McKenna et al, 2008). Because no single factor can identify those
patients with MGUS likely to progress to myeloma, patients need
to be monitored at regular intervals. Therefore, a diagnostic
method to identify those patients who are most at risk of cancer
progression would be of immense benefit to patients and would
raise the possibility of early treatment and improved prognosis.
Recently, a number of groups have investigated the efficacy of
microRNAs (miRNAs) as diagnostic or prognostic biomarkers.
miRNAs are small, non-coding RNAs that are known to regulate
gene expression (Jones and Newbury, 2010; Zen and Zhang, 2010;
Reid et al, 2011). At present, there are known to be 2042 (miRBase
19.0, Aug 2012) miRNAs encoded in the human genome, many of
which are specifically expressed in particular tissues. miRNAs can
bind to target mRNAs, usually in their 30 untranslated regions, and
cause downregulation of protein expression by translational
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repression or cleavage and degradation of the target mRNA (Kong
et al, 2012). Previous studies, using bone marrow plasma cells,
have suggested dysregulation of a set of miRNAs in myeloma,
including miR-181a/b, miR-17-92, miR-32, miR-193b-365, miR-
192-194-215 and miR-15a/16 (Pichiorri et al, 2008; Lionetti et al,
2009; Roccaro et al, 2009). These studies also found dysregulation
of miRNAs in MGUS patients (i.e., miR-21, miR-106-25, miR-181a/
b, miR-1 and miR-133). Although these changes in miRNA levels
shed light on the molecular mechanisms of multiple myeloma
malignancies, they are of limited use for a minimally invasive test
as the changes take place within bone marrow plasma cells.
The use of miRNAs as biomarkers has greatly increased as a result
of the discovery that they are present in the circulating blood. A
number of groups have shown that miRNAs can be detected in
human serum or plasma, where they are thought to be protected from
degradation by being encapsulated in microvesicles or exosomes and/
or are bound by RNA-binding proteins such as Ago2 and
nucleophosmin (Reid et al, 2011; Chen et al, 2012). Changes in levels
of particular subsets of circulating miRNAs have been associated with
various cancers. For example, in breast cancer patients, miR-195 and
let-7a have been found to be significantly upregulated in the sera of
patients with breast cancer compared with healthy, age-matched
subjects, whereas no significant difference was seen in levels of miR-
155 and miR-10b (Heneghan et al, 2010). These data therefore show
that it is feasible to use miRNAs derived from blood samples as a
minimally invasive diagnostic tool for cancer patients.
In the present study, we evaluated miRNA expression patterns
in the serum from the circulating blood derived from multiple
myeloma patients, MGUS patients and controls. We first used
microarray analysis to identify particular miRNAs that were
differentially expressed in pools of samples derived from each
participant group. We then examined individual samples, using
TaqMan real-time quantitative reverse transcription PCR (qRT–
PCR) to assess the abundance of particular mature miRNAs in
each sample. Using these methods we found three miRNAs, which
have potential as biomarkers in myeloma. Our data show that
circulating miRNAs provide a basis for a convenient and non-
invasive diagnostic test, which has potential prognostic value.
MATERIALS AND METHODS
Patient and control samples
For the initial identification of biomarkers, we used myeloma
patients, pre-cancerous MGUS patients, non-myeloma, non-MGUS
hospitalised patients and normal healthy controls without a family
history of haematological disease. All myeloma, MGUS and non-
myeloma, non-MGUS hospitalised patients were assessed by
serum/urine electrophoresis and serum-free light chain detection,
along with routine full blood count and biochemical profile (Kyle
and Rajkumar, 2008; McKenna et al, 2008). Patients with myeloma
and MGUS were subject to a bone marrow biopsy and skeletal
survey to stage their condition as per standard practice. The non-
myeloma, non-MGUS patients, who were admitted to the Brighton
and Sussex University Hospital because of similar symptoms to
that of myeloma patients, had no detectable paraprotein in their
serum. Relevant details on the patients used are given in Table 1.
Patient/control blood samples were collected in VACUETTE Gel Z
Serum Sep Clot Activator (Greiner Bio-One, Kremsmu¨enster,
Austria) 5ml, red/yellow tubes, and the serum was removed
according to normal hospital procedures. Serum samples were
stored at 4 1C for less than 7 days before freezing at  80 1C. All
samples from human participants were collected with informed
written consent, and the research was carried out under the
‘Brighton blood disorder study’, which has ethical and RþD
approval for donation of blood and marrow samples for research
purposes (references: 09/025/CHE and 09/H1107/1).
RNA extraction
Total RNA extraction was performed using a mirVana PARIS kit
(Life Technologies, Carlsbad, CA, USA), following the manufac-
turer’s instructions. Samples were not enriched for miRNAs. The
yields of total RNA were 140–360ng per 400ml of serum.
Microarrays
Agilent Human miRNA 8 15K Microarrays (Agilent, Santa Clara,
CA, USA, V3, miRBase version 12.0) were used according to the
manufacturer’s instructions. Hybridisation was performed using
Agilent hybridisation chambers in a rotary UVP HB-1000 oven.
The slides were scanned using an Axon GenePix 4000B Microarray
Scanner and analysed using GenePix Pro 6.0 (Molecular Devices,
Sunnyvale, CA, USA). Two arrays were used for each pooled
sample; because there were four pooled samples, this experiment
used one microarray slide of eight arrays. Each array contained 16
spots per miRNA, therefore 32 spots in total for each miRNA were
analysed for the four sample groups. On each array, a miRNA was
taken to have been detected if more than four of its spots were
visible above the background level. This equates to at least 8 out of
32 spots over both arrays. Microarray data has been deposited in
the ArrayExpress Archive, accession number E-MTAB-1254.
Quantitative PCR
TaqMan miRNA assays (Life Technologies) were used for
qRT–PCR. Reverse transcription was performed using a TaqMan
MicroRNA Reverse Transcription Kit (Life Technologies), and the
specific looped RT primers provided with was TaqMan assay. The
qRT–PCR was performed using the specific primer/probe combi-
nation provided with each TaqMan assay and TaqMan Universal
PCR Master Mix, No AmpErase UNG (Life Technologies). For
Table 1 Summary of clinical details of human participants used for
microarray analysis of serum samples
Patient groups n (%)
Normal healthy controls (N)
Total 13
Male 5 (38.5)
Female 8 (61.5)
Age on collection of sample
Range 42–58
Mean and s.d. 47.7±5.7
Normal hospitalised (NH) controls
Total 20
Male 9 (45)
Female 11 (55)
Age on collection of sample
Range 41–93
Mean and s.d. 76.1±13.2
MGUS (MG) patients
Total 15
Male 11 (73)
Female 4 (27)
Age on collection of sample
Range 50–81
Mean and s.d. 64.5±11.2
Myeloma (M) patients
Total 24
Male 12 (50)
Female 12 (50)
Age on collection of sample
Range 58–89
Mean and s.d. 73.5±7.8
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absolute quantification, synthetic miRNAs from Sigma-Aldrich
(St Louis, MO, USA) were used for standards. Two RT reactions
and two qPCRs were performed per RNA preparation from serum
(four technical replicates total). One RT reaction and three qPCRs
were performed for each standard (three technical replicates total).
RESULTS
Optimisation of RNA extraction techniques
Our search for a myeloma biomarker first required us to determine
the most robust and reliable method for extraction of miRNAs
from human serum. Serum, rather than plasma was the starting
material of choice because serum is normally used in the clinic in
serum electrophoresis tests to assess levels of paraprotein. miRNAs
are usually found at low levels in serum, therefore optimisation of
extraction was important. We tried three extraction methods:
Trizol/chloroform followed by isopropanol precipitation (using
500ml of serum), the mirVana PARIS kit (Life Technologies) (using
400ml of serum) and the Exiqon’s protocol using miRNeasy mini
kit (Qiagen, Hilden, Germany) (using 250ml of serum). Non-
myeloma, non-MGUS patients were chosen for this initial study.
Total RNA was extracted in triplicate, the yield and quality were
assessed using a Nanodrop spectrophotometer and the presence of
a particular mature miRNA (miR-181b) was assessed using
TaqMan real-time qRT–PCR. Of the three extraction methods
used, the mirVANA PARIS kit proved to provide the most
consistent results, with the highest yield of miRNA, as assessed by
the levels of miR-181b.
Identification of potential miRNA biomarkers using
microarrays
The next step was to identify miRNAs in serum from myeloma and
MGUS patients, which could act as a robust and reliable biomarker
for the disease. For this step, we chose to use miRNA microarrays,
as this platform identifies miRNAs by hybridisation to immobi-
lised nucleic acids, rather than using a PCR step. As each method
can have inherent bias (Git et al, 2010), we chose to initially
identify miRNAs using microarrays and then follow-up using a
PCR-based method.
To optimise this detection step, and to identify the miRNAs most
likely to be dysregulated, we chose to pool samples within patient
and control groups. This pooling method had the advantage that we
would only detect miRNAs that were expressed in the majority of
patients/subjects within the group. Therefore, this procedure reduced
variation between individuals and enriched for miRNAs most likely
to change between patient and control groups. The individuals used
per group were not more than 20. The four groups of serum samples
comprised normal, healthy controls (n¼ 13), non-MGUS/non-
myeloma patients (n¼ 20), patients who had low levels of
paraprotein in their serum (IgG, IgA o10g l 1 (n¼ 20)) and
patients who had high paraprotein in their serum (IgG, IgA
420g l 1 (n¼ 19)). These levels of paraprotein were used as a
criterion to clearly distinguish between patient groups. The use of
paraprotein levels to separate the latter two groups provided an easy,
quantitative way of distinguishing these two groups of patients. RNA
was extracted in duplicate from the pooled serum samples using the
mirVana PARIS kit as described above.
After the relevant quality control steps (see Materials and
Methods), nine miRNAs were reliably detected in all patient/
control groups by the Agilent Human miRNA arrays. These
miRNAs, listed in Table 2, were detected in at least two of the
patient or control groups. Note that our pooling method meant
that miRNAs expressed at low levels or expressed in only a few
individuals would not be detected. This enrichment process
therefore allowed us to concentrate on the few miRNAs that were
most likely to change between groups, as well as be detected at
reasonable levels in all individual samples. Our method of selecting
miRNAs for further study was also very rigorous; miRNAs were
only selected if the signal on the array was significantly above
background levels in at least 4 out of 16 spots (per miRNA per
array). The levels of these miRNAs were not compared between
groups using the array data as there is no known internal control
in serum for use as a normaliser to compensate for technical
variations between arrays.
Validation of array results using real-time RT–PCR
To validate the microarray results and confirm the pattern of
miRNA expression between patient/control samples, TaqMan
qRT–PCR assays were employed. The qRT–PCR is more sensitive
and more quantitative over a greater dynamic range than
microarrays. TaqMan assays were available and worked reliably
for six of the nine miRNAs detected on the arrays. These six assays
were tested on each of the replicated RNA samples (i.e., N1/N2
etc.) from pooled serum used on the arrays. Two reverse-
transcriptase replicates and two PCR replicates were carried out
for each pooled sample, giving eight replicates for each pool in
total. All six miRNAs were detected in both replicates of each
group with the expression pattern of each miRNA being different
for each patient group. Of these six potential miRNA biomarkers,
three were chosen for further investigation; miR-720, miR-1246
and miR-1308. These were selected because they are expressed at
reasonably high levels (i.e., at Cts of 19–27) and show different
patterns of expression between patient and control groups. Note
that recent re-evaluation of the miRNAs in the miRbase database
has shown that miR-1308 is not a miRNA but is a 50-cleaved
fragment of a GlyGCC tRNA. Although accurate quantification of
expression differences between samples is not possible because of
the lack of a normaliser miRNA, it seems likely that these
differences reflect true biological differences as the technical
variation between qPCR tests was minimal.
Absolute quantitation of miRNA levels in individual serum
samples
At present, there is no reliable normaliser (or reference control)
available for use in qRT–PCR assays on miRNA samples extracted
from human serum. The mRNAs that are often used for analysis of
gene expression in tissues (e.g., GAPDH) are not found in
circulating blood, presumably because they are not protected by
microvesicles/exosomes. Small non-coding nuclear RNAs, such as
Table 2 miRNAs detected in pooled patient and control samples, as
detected by Agilent Human miRNA microarrays
miRNA Sequence
hsa-miR-451 50-AAACCGUUACCAUUACUGAGUU-30
hsa-miR-638 50-AGGGAUCGCGGGCGGGUGGCGGCCU-30
hsa-miR-720 50-UCUCGCUGGGGCCUCCA-30
hsa-miR-1246 50-AAUGGAUUUUUGGAGCAGG-30
hsa-miR-1308 50-GCAUGGGUGGUUCAGUGG-30
hsa-miR-1915 50-CCCCAGGGCGACGCGGCGGG-30
hsa-miR-1974 50-UGGUUGUAGUCCGUGCGAGAAUA-30
hsa-miR-574-5p 50-UGAGUGUGUGUGUGUGAGUGUGU-30
hsa-miR-762 50-GGGGCUGGGGCCGGGGCCGAGC-30
All of these showed potential as biomarkers as the levels of miRNAs varied between
the patient and control groups. The expression levels of six of these miRNAs (in
bold) were verified using TaqMan qRT–PCR. Three miRNAs (miR-720, miR-1246
and miR-1308) chosen for further analysis in individual patient samples. TaqMan
qRT–PCR assays for the remaining three miRNAs were not available or were
unreliable.
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RNU44, which are often used as normaliser RNAs in qRT–PCR
experiments, have been shown by ourselves and others to be
absent from serum samples (Zhu et al, 2009). Although some
snoRNAs, snRNAs and rRNAs can be detected in serum, their
expression is quite variable (Hunter et al, 2008). miR-16 has been
used as a normaliser in some studies, but we did not find it to be
expressed at similar levels between patient and control samples.
Other groups have standardised miRNA levels according to the
total amount of RNAs extracted from a particular quantity of
serum, but this is not satisfactory, as patients with cancer can have
significantly more total miRNAs in their serum than normal
controls (Lodes et al, 2009). Spike-in controls, often using
Caenorhabditis elegans miRNAs, which are not found in humans
(e.g., cel-miR-39) (Mitchell et al, 2008) can be used to determine
the miRNA extraction efficiency. However, these are of limited
value when comparing miRNA levels between patients.
To accurately determine the expression differences between
groups, we performed absolute quantification to determine the
copy number of each miRNA per ml of serum. At present, this
appears to be the only way of accurately determining the
differences in miRNA levels between individual patients and
controls. Absolute quantification requires standard samples to be
run alongside unknown samples for comparison. The standards
used must be the miRNA of interest at a known concentration, for
example, miRNAs produced synthetically. The synthetic miRNA is
diluted across a range of several orders of magnitude, and these
dilutions are treated in the same way as the unknown samples. The
standard samples are used to plot a curve of cycle threshold (Ct) vs
copy number, and the Ct of the unknown samples is compared
with this to give a copy number. The copy numbers from
individuals can then be compared between groups to show
differences in expression.
Comparison of levels of miR-720, miR-1245 and miR-1308
in individual patients
In order to determine the pattern of miRNA expression in
serum in individual patients and controls, RNA was prepared from
200ml of serum from the individual patients/controls that had
formed the pools for earlier experiments. Two RT reactions were
performed per patient/control followed by two technical replicates
for each (four technical replicates per individual/miRNA combina-
tion). The absolute amounts of each miRNA, per ml of serum in each
patient sample were determined as above using the corresponding
synthetic miRNA to generate the standard curve (Figure 1).
As can be seen from Figure 1, the pattern of expression of each
miRNA differs between patient groups. For miR-720, the levels are
significantly higher in myeloma and MGUS patients compared
with normal controls, whereas the levels of miR-1308 are
significantly lower in patients compared with normal controls.
The different patterns of expression of miRNAs suggest indepen-
dent control of each miRNA by the cells secreting the miRNAs.
Second, for all three miRNAs, the levels of miRNAs are much more
tightly grouped in the normal controls compared with the patient
groups. These data suggest that levels of these miRNAs in serum
are normally tightly controlled and are dysregulated in disease.
Our results further suggest that miRNAs can be used as a diagnosis
test for MGUS and myeloma.
The non-MGUS, non-myeloma group show a wider range of
expression compared with the other groups. These patients had no
detectable paraprotein in their blood, and were subsequently
diagnosed with a variety of illnesses unrelated to myeloma. These
illnesses included hypercalcaemia attributable to underlying
malignancy and patients with anaemia associated with renal
failure. Various malignancies and renal impairment, in particular
chronic renal impairment, have previously been shown to be
associated with distinct miRNA signature in serum (Neal et al,
2011). Therefore, the range of miRNA expression in these patients
is likely to reflect the wide range of diseases from which they are
suffering.
The graphs also show that the pattern of expression of each of
the three miRNAs, miR-720, miR-1246 and miR-1308, are similar
between MGUS and myeloma patients. This is to be expected as
MGUS is well established as a pre-cancerous state for myeloma. It
is also interesting to note that the miRNAs we have detected as
biomarkers in the serum are different from those dysregulated in
plasma cells (Pichiorri et al, 2008; Lionetti et al, 2009; Roccaro
et al, 2009).
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Figure 1 Comparison of the serum levels of miR-720 (A), miR-1308 (B) and miR-1246 (C) in Normal (N), Normal hospitalised (NH), MGUS (MG) and
myeloma (M) groups. Graphs show median level with interquartile range. The Kruskal–Wallis test with Dunn’s post test was used to determine the
significance of differences between groups. The serum levels were determined using TaqMan miRNA qRT–PCR following RNA extraction. Two technical
replicates were performed on two cDNA replicates (four technical replicates total per sample/miRNA combination.
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miR-720 and miR-1308 provide a biomarker signature,
which can distinguish MGUS and myeloma patients from
normal healthy controls
Analysis of the levels of miR-720 shows that it can be used
to distinguish normal, healthy controls from all other patient
groups (Figure 1A). In particular, miRNA levels are significantly
higher in myeloma patients than healthy controls, where the
median miRNA concentration in myeloma is 17 616 copies per ml
compared with 5951 copies per ml in normal subjects (Po0.001,
Kruskal–Wallis test with Dunn’s post test). We also used receiver
operating characteristic (ROC) curves, which can be used to
determine the true-positive and true-negative rates of a diagnostic
test. Figure 2A shows that serum miR-720 yielded an AUC (the
area under the ROC curve) of 0.9112 (Po0.001) with 87.2%
sensitivity and 92.3% specificity for discriminating MGUS and
myeloma patients from healthy controls at a cut-off value of
5773 copies per ml. Therefore, use of miR-720 alone provides
excellent discrimination between healthy subjects and MGUS or
myeloma patients.
For miR-1308, the concentration of this miRNA is significantly
lower in MGUS and myeloma patients compared with normal
healthy controls (Po0.01, Figure 1B). The median concentration of
this miRNA in myeloma patients is 157 020 copies per ml compared
with 659 640 copies per ml in normal subjects. Similarly to miR-
720, it appears that serum miR-1308 is a potential marker for
discriminating MGUS and myeloma patients from healthy controls
with an AUC of 0.892 (Po0.001; Figure 2B). At a cut-off value of
405 400 copies per ml, the sensitivity for this marker is 82.1% and
the specificity is 92.3%. The serum concentrations of miR-1246 are
not able to distinguish patients with MGUS or myeloma from
healthy controls (Figure 2C).
miR-1308 and miR-1246 provide a biomarker signature
that can distinguish patients with unrelated illnesses from
MGUS and myeloma patients
It is important that the miRNA biomarkers can distinguish
patients with MGUS or myeloma from patients with unrelated
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Figure 2 ROC curves to compare the ability of each miRNA, or combinations of miRNAs, to distinguish between different groups. (A) miR-720 can
clearly distinguish between N and MG/M groups (Po0.001). (B) miR-1308 can also distinguish between N and MG/M groups (Po0.001). (C) miR-1246
cannot clearly distinguish between N and MG/M groups. (D) miR-720 cannot clearly distinguish between NH and MG/M groups. (E) miR-1308 can
distinguish between NH and MG/M groups (Po0.05) (F) miR-1246 can also distinguish between NH and MG/M groups (Po0.05) (G) The combination of
miR-720 and miR-1308 ([miR-1308]/[miR-720]) can clearly distinguish between N and MG/M groups (Po0.05). (H) The combination of miR-720 and miR-
1308 can distinguish between the NH and MG/M groups (Po0.05). (I) When the N and NH groups are considered together, the combination of miR-720
and miR-1308 can distinguish between the N/NH and MG/M groups (Po0.001).
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illnesses who have some of the symptoms of myeloma, for
example, protein in the urine (proteinuria). Such a test would be
useful in a hospital setting to aid in the diagnosis of myeloma.
Analysis of the levels of serum miR-1308 using a ROC curve shows
that it can be used to distinguish MGUS and myeloma from
hospitalised patients without these illnesses with an AUC of 0.6577
(sensitivity of 74.4% and specificity of 65.0% at a cut-off value of
230 850 copies per ml; Po0.05; Figure 2E). miR-1246 gives a similar
result with a AUC of 0.6615 (sensitivity of 56.4% and specificity of
80.0% at a cut-off value of 418 150 copies per ml; Po0.05;
Figure 2F). Therefore, these biomarkers show potential in
distinguishing MGUS and myeloma patients from patients with
unrelated illnesses, as well as from healthy controls.
The use of miRNAs in combination provides a more
powerful diagnostic tool for distinguishing MGUS and
myeloma patients
The use of miR-720 and miR-1308 together provides an even more
powerful diagnostic tool for distinguishing normal healthy
controls from MGUS and myeloma patients. By dividing the
concentration of miR-1308 in the serum by that of miR-720 (i.e.,
[miR-1308]/[miR-720]), the AUC rises to 0.9862 (Po0.001) with a
sensitivity of 97.4% and a specificity of 92.3% at a cut-off value of
83.9 (Figure 2G). In other words, this test gives only 7.7% false
positives and 2.6% false negatives. Therefore, this result shows the
great potential of using miRNAs, in combination, to produce
predictive diagnostic tests. The miRNAs miR-1308 and miR-720 in
combination can also be used to improve the distinction between
non-myeloma, non-MGUS patients (NH) and MGUS and myeloma
patients (MG/M). Figure 2H shows a significant difference between
these groups (Po0.05) with the AUC rising to 0.6987 (sensitivity of
64.1% and a specificity of 75.0% at a cut-off value of 13.9). This
combination of miRNAs can also distinguish the normal healthy
and non-MGUS, non-myeloma groups (considered together) from
the MGUS and myeloma groups. Figure 2I shows that the AUC is
0.8120 (Po0.001), with a sensitivity of 64.1% and a specificity of
84.9% at a cut-off value of 13.85. Importantly, these data show that
[miR-1308]/[miR-720] could be used as a diagnostic tool for both
hospitalised patients as well as for screening apparently healthy
individuals.
miR-1246 and miR-1308, in combination, can provide
a biomarker signature that has potential to distinguish
MGUS from myeloma patients
One of the key aims of this work is to use miRNAs to distinguish
MGUS from myeloma patients. This is the first step on the way to
providing a prognostic test that can predict which MGUS patients
are likely to progress to myeloma. Our results (Figures 3A–D)
show that single miRNAs cannot distinguish the two conditions
(Figures 1A–C and Figures 3A–C). The combination of [miR-
1308]/[miR-720] is also unable to make the distinction
(Figure 3D). However, the combination of miR-1246 and miR-
1308 (i.e., concentration of [miR-1246]/[miR-1308]) can distin-
guish these conditions to some extent (Figure 3E). The ROC plot of
[miR-1246]/[miR-1308] shows reasonable separation between the
two groups (AUC¼ 0.7250; Po0.05), with a sensitivity of 79.2%
and specificity of 66.7% at a cut-off value of 6.4). We would expect
that analysis of more miRNAs would improve the sensitivity and
specificity for distinguishing these patient groups.
The levels of miR-720, miR-1245 and miR-1308 do not
change appreciably with age or gender
One of the attributes of good biomarkers is that they do not change
appreciably with age or gender. In order to find out whether these
particular miRNAs change with age in the individual patients
studied, the copy numbers per ml of each of the miRNAs were
plotted against age for all patients and controls (Figure 4). When
the samples from all groups were considered together, a very slight
positive correlation was detected between miR-720 concentration
and age (Figure 4A). No significant correlation was observed
between miR-1246 or miR-1308 concentration and age for any
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sample groupings even when all samples were considered together
(Figures 4A–C). When the samples from all groups were
considered together, a very slight positive correlation was detected
between miR-720 concentration and age (Figure 4A). No
significant correlation was observed between miR-1246 or miR-
1308 concentration and age for any sample groupings even when
all samples were considered together (Figures 4B and C). The
significance of all the weak correlations observed was lost upon
correction for multiple significance tests using the Bonferroni
method (not shown). Overall, we conclude that any correlation
between the expression of these miRNAs and age is too weak to
affect the utility of these miRNAs as biomarkers for myeloma.
Similarly, diagnostic tests are simplified if there are no
differences in expression of biomarkers between male and female
patients. Our data show that the miRNAs tested show no difference
in copies per ml between men and women for all three miRNAs
(Figures 4D–F).
miR-720 and miR-1308 expression levels in serum are not
correlated with paraprotein
The criteria for diagnosis of myeloma includes levels of M-protein
in the blood of 430 g l 1 (Swerdlow et al, 2008). However, this is
only one aspect of the diagnosis; the severity of the disease and the
likelihood of progression to the cancerous state are not particularly
well correlated with the amount of paraprotein in the serum. For
example, patients with smouldering myeloma do not, by defini-
tion, exhibit lytic bone lesions or impaired renal function, which
are indicative of myeloma. The clinical data therefore suggest that
myeloma is not purely due to mutations resulting in increased
paraprotein levels but also requires further mutations to transform
the plasma cells to a cancerous state. The amounts of miRNAs we
see in circulating blood could reflect that of paraprotein levels or
could alternatively provide us with additional information about
underlying gene-expression changes that occur upon cancer
progression.
Paraprotein and absolute miRNA levels are plotted in Figure 5.
These data show that miR-720 and miR-1308 are not correlated
with paraprotein in the blood. However, there is slight significant
negative correlation of miR-1246 (P¼ 0.0115) with paraprotein.
These results suggest that the molecular mechanisms controlling
the levels of circulating miR-720 and miR-1308 are not linked to
the increased production of paraprotein. However, it is possible
that miR-1246 may be involved in, or be repressed by, increased
paraprotein production or secretion.
Expression of miR-720 and miR-1246 are correlated
At present, little is known about the control of secretion of
miRNAs into the circulating blood (Reid et al, 2011). However, it is
possible that dysregulation of miRNA production or secretion are
co-ordinately regulated. To determine whether the concentrations
of miR-720, miR-1308 and miR-1246 in serum are co-ordinately
regulated, we analysed their correlation with each other. Data
presented in Figure 6A show that the expression of miR-720 and
miR-1308 is not significantly correlated in any of the patient or
control groups. However, levels of miR-720 and miR-1246 do
correlate significantly, as an increased concentration of miR-720 is
associated with an increase in concentration of miR-1246 in all
patient and control groups (r¼ 0.4648, Po0.001). Interestingly,
miR-1308 and miR-1246 show a significant positive correlation
(r¼ 0.5524, Po0.001) only in MGUS and myeloma patients,
whereas no correlation is seen with normal healthy controls and
non-MGUS/non-myeloma patients (Figure 6C). It would therefore
appear that miR-720 and miR-1246 are co-ordinately regulated,
whereas miR-1308 is under different regulatory control.
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DISCUSSION
In this study, we used microarray analysis, followed by TaqMan
qRT–PCR to screen human miRNAs for potential to act as
biomarkers in multiple myeloma. The patient groups included
patients diagnosed with multiple myeloma, patients with the pre-
cancerous condition MGUS, hospitalised patients without MGUS
or myeloma and normal, healthy controls. Three miRNAs, miR-
720, miR-1246 and miR-1308, were identified and then validated
in individual patient samples. Use of miR-1308 and miR-720 in
combination (i.e., [miR-1308]/[miR-720]) showed excellent speci-
ficity and selectivity in distinguishing MGUS/myeloma patients
from normal, healthy controls (Figure 2). This combination of
miRNAs (i.e., [miR-1308]/[miR-720]) can also be used to
distinguish MGUS and myeloma patients from those with
unrelated illnesses. Therefore, these miRNAs show great potential
for a diagnostic test, which can be used both in the clinic and for
screening the general population. We have also shown that miR-
1246 and miR-1308 in combination (i.e., [miR-1246]/[miR-1308])
can distinguish myeloma from MGUS patients (Figures 2 and 3).
This is the first time that serum miRNAs have been shown to act as
useful diagnostic and prognostic biomarkers in multiple myeloma.
An unusual aspect of our work is that we performed absolute
quantitation of miRNAs in serum to give the number of molecules
per ml. This allows accurate quantitation of miRNA levels between
patient/control samples. Although certain miRNAs, snRNPs or
ribosomal RNAs have previously been used for normalisation
between serum samples (Reid et al, 2011), we found that these
non-coding RNAs were either not detected or changed in levels
between patient and control groups. As a suitable normalisation
control has not yet been established for use in human serum, the
use of absolute quantitation is at present the best way of
comparing miRNA levels between individual patients/controls. It
is very important that normalisation is performed correctly as use
of an inappropriate normaliser may give misleading results and
may explain some of the conflicting reports of patterns of miRNA
expression that have been given in previous reports.
Our results also show that the distribution of miRNAs detected
are similar between MGUS and myeloma patients. This is to be
expected as myeloma is a well-known development from the
MGUS condition (Kyle and Rajkumar, 2008). However, for all
miRNAs, the range of miRNA expression is more widely
distributed than for myeloma. This effect could be explained if
the onset of myeloma requires increased DNA hypermethylation to
shut down more miRNA-encoding genes than in MGUS (similarly
to coding genes as previously described (Walker et al, 2012). It is
also interesting to note that the miRNAs in serum, which we have
found to be useful as a biomarker for myeloma or MGUS, do not
overlap with miRNAs within plasma cells that are thought to be
associated with the cancerous state (Pichiorri et al, 2008; Lionetti
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et al, 2009; Roccaro et al, 2009). Therefore, it would appear that the
miRNAs in serum are either selectively secreted or that the
miRNAs in serum are produced by other cells within the body.
Our data also show that miR-720 and miR-1308 levels are not
significantly correlated with the levels of paraprotein in the blood
(Figure 5). These data suggest that miR-720 and miR-1308 are
providing different information on the pre-cancerous and
cancerous state that is not related to the dysregulation of gene
expression, resulting in overexpression of paraprotein. Because
high levels of M-component in the blood are not always related to
the cancerous state, as is the case in smouldering myeloma, these
miRNA biomarkers are likely to be providing alternative and
potentially useful information on the progression of the disease.
The miRNAs that we have found to be dysregulated in MGUS
and myeloma patients have not yet been found in the circulating
blood in association with other cancers. This is an advantage as far
as a diagnostic test is concerned because these miRNAs are more
likely to provide an extremely specific test for MGUS and
myeloma. In contrast, some miRNAs, such as miR-155, have been
shown to be upregulated in the sera of patients with a number of
different cancers, including diffuse large B-cell lymphoma and
breast cancer (Faraoni et al, 2009; Roth et al, 2010). The mRNA
targets of the miRNAs that we have detected have not yet been
experimentally determined, but miR-720 and miR-1246 have an
association with control of apoptosis, suggesting that they could
be shed by cells undergoing programmed cell death (Chikh et al,
2011).
Analysis of our data has shown that miR-1308 is expressed in a
different pattern than miR-720 and miR-1246 in that the levels of
this miRNA generally decrease (rather than increase) in MGUS and
myeloma patient sera compared with controls (Figure 1). In
addition, the expression of miR-1308 is not correlated with that of
miR-720 or miR-1246 (Figure 6). It is now known that miR-1308 is
not a miRNA but is a 50-cleaved fragment of a GlyGCC tRNA. The
presence of modified ribonucleosides in the serum of humans and
mice (Borek et al, 1977; Speer et al, 1979) has previously suggested
that tRNA fragments may be present in the circulating blood.
However, our data show, for the first time, that the intact 50 half of
a tRNA is present in human serum. Our finding that this cleaved
tRNA is differentially expressed in the serum of myeloma and
MGUS patients compared with controls is entirely novel and shows
that these cleaved tRNAs also have potential as diagnostic and
prognostic biomarkers.
The miRNA signature that we have identified for myeloma also
has other potential benefits for myeloma patients. For example,
this serum miRNA signature could be useful to pharmaceutical
companies for monitoring patient responses to new drug
treatments or regimes. In addition, the miRNA signature could
be used for myeloma stratification, prognosis estimation, predic-
tion of therapeutic efficacy, maintenance of surveillance following
treatment or forecasting of disease recurrence. Finally, this study
sets the stage for future analysis of other potential miRNA
biomarkers in a variety of ethnic groups in order to improve
prognosis/diagnosis of myeloma and predictions of therapeutic
responses.
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